The CTNG testing market is projected to be worth USD 1.8 billion in 2024. The market is anticipated to reach USD 3.9 billion by 2034. The market is further expected to surge at a CAGR of 8.0% during the forecast period 2024 to 2034.
Key Market Trends and Highlights
The expansion of healthcare infrastructure, particularly in emerging economies, creates opportunities for increased access to CTNG testing services, leading to market expansion.
| Attributes | Key Insights |
|---|---|
| CTNG Testing Market Estimated Size in 2024 | USD 1.8 billion |
| Projected Market Value in 2034 | USD 3.9 billion |
| Value-based CAGR from 2024 to 2034 | 8.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The scope for CTNG testing rose at a 10.2% CAGR between 2019 and 2023. The global market is anticipated to grow at a moderate CAGR of 8.0% over the forecast period 2024 to 2034.
The CTNG testing Market witnessed steady growth during the historical period, driven by factors such as increasing awareness about STIs, advancements in diagnostic technologies, and expansion of healthcare infrastructure.
Significant advancements in CTNG testing technologies, including the introduction of multi parameter CT/NG NAATs and point of care testing solutions, enhanced the accuracy, sensitivity, and accessibility of diagnostic tests.
The rising incidence of chlamydia and gonorrhea infections globally, coupled with the emergence of antibiotic resistant strains, underscored the need for effective screening and detection methods, driving market demand.
The forecast period is expected to witness continued technological innovations in CTNG testing, including the development of next generation molecular assays, advanced point of care devices, and integrated diagnostic platforms, driving market expansion.
The increasing demand for point of care testing solutions for STIs, driven by the need for rapid and convenient diagnostics in diverse healthcare settings, is expected to fuel market growth during the forecast period.
The expansion of telemedicine platforms and remote testing services is anticipated to facilitate broader access to CTNG testing, particularly in underserved rural areas and resource limited settings, contributing to market expansion.
Increasing awareness about sexually transmitted infections, including chlamydia and gonorrhea, among the population drives the demand for CTNG testing.
Principal Consultant
The cost associated with CTNG testing procedures, including diagnostic kits, laboratory equipment, and personnel training, can be prohibitive for healthcare providers and patients, hindering widespread adoption and accessibility.
The below table showcases revenues in terms of the top 5 leading countries, spearheaded by Korea and the United Kingdom. The countries are expected to lead the market through 2034.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 8.3% |
| The United Kingdom | 9.3% |
| Japan | 9.0% |
| China | 8.7% |
| Korea | 9.8% |
The CTNG testing market in the United States expected to expand at a CAGR of 8.3% through 2034. The country has seen a rise in the prevalence of chlamydia and gonorrhea infections, particularly among sexually active individuals and high risk populations, driving the demand for CTNG testing services to address the public health burden of these STIs.
Stringent regulatory requirements set by organizations such as the Food and Drug Administration mandate the need for comprehensive CTNG testing as part of regulatory approvals for medical devices, diagnostics, and pharmaceutical products, fostering market growth.
The CTNG testing market in the United Kingdom is anticipated to expand at a CAGR of 9.3% through 2034.
The implementation of national screening programs, such as the National Chlamydia Screening Program and the National Gonorrhea Screening Programme, promotes routine CTNG testing among sexually active individuals, contributing to increased testing rates and early detection of infections.
Government funding and support for STI prevention, control, and screening initiatives, including investments in sexual health services and public health campaigns, drive the implementation of CTNG testing services and raise public awareness about the importance of STI screening and treatment.
CTNG testing trends in China are taking a turn for the better. An 8.7% CAGR is forecast for the country from 2024 to 2034.
The expansion of healthcare infrastructure in China, including the establishment of sexual health clinics, community health centers, and primary care facilities, facilitates access to CTNG testing services for individuals seeking sexual health care, particularly in urban and rural areas.
Increasing awareness about STIs and sexual health issues, driven by educational initiatives, media campaigns, and community outreach programs, encourages individuals to seek CTNG testing services and promotes safe sexual practices, reducing the spread of STIs.
The CTNG testing market in Japan is poised to expand at a CAGR of 9.0% through 2034. Ongoing advancements in CTNG testing technologies, including nucleic acid amplification tests, molecular assays, and point of care testing devices, enhance the accuracy, sensitivity, and accessibility of testing services, driving market adoption and utilization.
Increased investments by private sector companies in STI diagnostics and healthcare services, coupled with market liberalization policies, stimulate competition, innovation, and market growth in the market.
The CTNG testing market in Korea is anticipated to expand at a CAGR of 9.8% through 2034.
The emergence of antibiotic resistant strains of chlamydia and gonorrhea in Korea highlights the importance of early detection and appropriate treatment, driving the demand for CTNG testing services to guide therapeutic decisions and prevent the spread of drug resistant infections.
Increasing emphasis on sexual health education in schools, universities, and community organizations raises awareness about STIs, promotes safe sexual practices, and encourages regular STI screening among young people and at risk populations, driving the demand for CTNG testing services.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below table highlights how assays and kits segment is projected to lead the market in terms of product, and is expected to account for a CAGR of 7.7% through 2034. Based on test type, the laboratory segment is expected to account for a CAGR of 7.5% through 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Assays and Kits | 7.7% |
| Laboratory | 7.5% |
Based on product, the assays and kits segment is expected to continue dominating the CTNG testing market. Ongoing advancements in assay and kit technologies, including nucleic acid amplification tests, polymerase chain reaction, and loop mediated isothermal amplification, enhance the sensitivity, specificity, and speed of CTNG detection, driving demand for assay and kit products.
Assays and kits offer high levels of accuracy and reliability in detecting chlamydia and gonorrhea infections, making them essential tools for healthcare providers and laboratories conducting routine screening, diagnosis, and surveillance programs.
Assays and kits are designed to be user friendly, with standardized protocols and procedures that simplify sample collection, processing, and interpretation, enabling healthcare professionals to perform CTNG testing efficiently in diverse clinical and laboratory settings.
In terms of test type, the laboratory segment is expected to continue dominating the CTNG testing market, attributed to several key factors. Laboratory based tests offer high levels of accuracy and precision in detecting chlamydia and gonorrhea infections, making them the gold standard for diagnosis and confirmation of STIs.
Laboratories have the infrastructure, equipment, and expertise to perform comprehensive CTNG testing, including nucleic acid amplification tests, culture based methods, and antimicrobial susceptibility testing, enabling thorough assessment and characterization of STI pathogens.
Laboratories offer specialized testing services, such as genotyping, serotyping, and molecular epidemiology, to identify strain variations, antimicrobial resistance patterns, and transmission dynamics of chlamydia and gonorrhea pathogens, facilitating targeted treatment and public health interventions.
The competitive landscape of the CTNG testing market is characterized by the presence of several established players, emerging companies, and innovative startups competing to gain market share and meet the growing demand for accurate, reliable, and accessible testing solutions for chlamydia and gonorrhea infections.
Company Portfolio
| Attribute | Details |
|---|---|
| Estimated Market Size in 2024 | USD 1.8 billion |
| Projected Market Valuation in 2034 | USD 3.9 billion |
| Value-based CAGR 2024 to 2034 | 8.0% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD Billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Key Market Segments Covered | Product, Test Type, Technology, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, France, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Hologic Inc.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Bio-Rad Laboratories Inc.; Siemens Healthineers AG; Danaher; Becton, Dickinson and Company; bioMérieux SA |
The CTNG testing market is projected to reach a valuation of USD 1.8 Billion in 2024.
The CTNG testing industry is set to expand by a CAGR of 8.0% through 2034.
The CTNG testing market is forecast to reach USD 3.9 Billion by 2034.
Korea is expected to be the top performing market, exhibiting a CAGR of 9.8% through 2034.
Assays and kits segment is preferred, and is expected to account for a CAGR of 7.7% through 2034.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Assays & Kits 5.2. Instruments/Analyzers 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Test Type 6.1. Laboratory 6.2. Point-of-Care Testing 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology 7.1. INAAT 7.2. PCR 7.3. Immunodiagnostics 7.4. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. F. Hoffmann-La Roche Ltd. (Switzerland) 18.2. Hologic, Inc. (USA) 18.3. Thermo Fisher Scientific Inc. (USA) 18.4. Abbott Laboratories (USA) 18.5. Bio-Rad Laboratories, Inc. (USA) 18.6. Siemens Healthineers AG (Germany) 18.7. Danaher (USA) 18.8. Becton 18.9. Dickinson and Company (USA) 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
CTNG Testing Market
